Table 4.
The allele frequencies of human leukocyte antigen-C (HLA-C) in the patients with Kawasaki disease and the control subjects
| HLA alleles | Healthy controls (n = 159) n (%) | KD patients (n = 74) n (%) | Coronary complications | |
|---|---|---|---|---|
| Present (n = 21) n (%) | Absent (n = 53) n (%) | |||
| HLA-Cw | ||||
| 01 | 59 (37.1) | 22 (29.7) | 6 (28.6) | 16 (30.2) |
| 02 | 0 (0.0) | 1 (1.4) | 0 (0.0) | 1 (1.9) |
| 04 | 21 (13.2) | 11 (14.9) | 2 (9.5) | 9 (17.0) |
| 05 | 6 (3.8) | 1 (1.4) | 0 (0.0) | 1 (1.9) |
| 06 | 25 (15.7) | 10 (13.5) | 5 (23.8) | 5 (9.4) |
| 07 | 44 (27.7) | 20 (27.0) | 6 (28.6) | 14 (26.4) |
| 08 | 29 (18.2) | 10 (13.5) | 3 (14.3) | 7 (13.2) |
| 09 | 23 (14.5) | 19 (25.7)a | 5 (23.8) | 14 (26.4)b |
| 10 | 39 (24.5) | 24 (32.4) | 5 (23.8) | 19 (35.8) |
| 12 | 11 (6.9) | 4 (5.4) | 2 (9.5) | 2 (3.8) |
| 14 | 34 (21.4) | 18 (24.3) | 7 (33.3) | 11 (20.8) |
| 15 | 8 (5.0) | 1 (1.4) | 1 (4.8) | 0 (0.0) |
KD, Kawasaki disease; RR, relative risk
ap < 0.04; RR = 2.0 (95% confidence interval [CI], 0.97–4.29) vs healthy control subjects
bp < 0.05; RR = 2.1 (95% CI, 0.92–4.87) vs healthy control subjects